Abstract Body

Gallant efforts are ongoing to achieve sustained antiretroviral therapy (ART)–free HIV remission. With the exception of 2 stem-cell transplantation cases and the few instances of natural control, this has been proven challenging. Recent advances have highlighted the importance of myeloid reservoirs as sanctuaries of HIV persistence and therefore may partially be responsible for viral recrudescence following analytical antiretroviral treatment interruption. The ongoing debate in the field as to whether the central nervous system (CNS), encompassing the brain, spinal cord, and its cellular bodies–including myeloid cells, continues as to their contribution as sites of HIV persistence of latent replication or non-replication competent virus in the setting of ART. Further, most current human HIV cure–targeted clinical studies have primarily focused these efforts on targeting viral persistence in CD4 T cells in blood and tissue sanctuaries, and the lack of myeloid-centered HIV clinical trials focused on the CNS reservoir, either as primary or secondary end points, has hindered our understanding of the contribution of myeloid cells and the CNS as viral sanctuaries of rebound virus and may guide successes in future HIV eradication strategies. This presentation will highlight controversies, boundaries to overcome and new research efforts defining myeloid reservoirs and HIV persistence in the CNS and recent advances in HIV remission and cure trials that would be relevant in targeting this compartment, and make an argument as to their clinical relevancy as we progress towards sustained ART-free HIV remission in all people with HIV.